Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/30/15
End: 03/08/17
Due: 03/08/18
Phase: N/A
Priority: Normal
Start: 12/03/19
End: 03/29/23
Due: 03/29/24
Phase: N/A
Priority: Normal
Start: 01/30/19
End: 03/03/21
Due: 03/03/22
Phase: N/A
Priority: Normal
Start: 09/17/21
End: 06/30/26
Due: 06/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| ADC-1013 First-in-Human Study | NCT02379741 | Alligator Bioscience AB | user2@example.com | None | 2015-04-30 | 2017-03-08 | 2018-03-08 | - | - | 2025-07-14 |
| Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017 | NCT04144842 | Alligator Bioscience AB | user2@example.com | None | 2019-12-03 | 2023-03-29 | 2024-03-29 | - | - | 2025-07-14 |
| Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015 | NCT03782467 | Alligator Bioscience AB | user2@example.com | None | 2019-01-30 | 2021-03-03 | 2022-03-03 | - | - | 2025-07-14 |
| Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients | NCT04888312 | Alligator Bioscience AB | user2@example.com | None | 2021-09-17 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |